VERZENIO
PeakNDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
VERZENIO by Eli Lilly and Company is cyclin-dependent kinases 4 and 6 (cdk4 and cdk6). First approved in 2018.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERZENIO is an oral small-molecule CDK4/6 inhibitor approved in 2018 for breast cancer treatment. It is used in combination with endocrine therapy or as monotherapy in specific patient populations. The drug works by inhibiting cyclin-dependent kinases 4 and 6, slowing cancer cell proliferation.
$0.757BPart D
PeakPeak lifecycle stage with substantial Part D spend signals a mature, established brand with stable commercial teams and ongoing market defense initiatives.
Mechanism of Action
cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast
Started Mar 2022
1,500 enrolled
The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
Why This Matters for Your Career
Worked on VERZENIO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.